Oncology Data Advisor

Read the full article here! https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.

Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient? In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on: 🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles. 🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy. 🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients. 📅 Save Your Spot for the Live Event! Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman. Session 1: July 8 at 6:00 pm ET: bit.ly/3SitVaC Session 2: July 28 at 7:00 pm ET: bit.ly/4oIAcZo

View the full article at: https://oncdata.com/oncology-unfiltered-tumor-board-vs-tuesday-afternoon Tumor boards play a pivotal role in oncology care. For clinicians, they represent the ideal environment: multiple specialists, shared context, and time to debate the gray areas that guidelines can’t fully capture. However, during a busy afternoon in the clinic, the plans developed in tumor boards often prove less straightforward to implement. In this episode of Oncology Unfiltered, Melissa Cutrona, MS, and Matthew Hadfield, DO, OncData Editor in Chief, unpack why tumor boards are so valuable, where they fall short, and how to bridge the gap between a coordinated plan and the reality of care delivery on a busy clinic day.

Check out the full article at: https://oncdata.com/oncology-unfiltered-the-real-world-vs-the-trial-patient Every oncologist knows the moment well: you're reviewing treatment options with a patient, guidelines in hand, when you realize the person sitting across from you wouldn't have qualified for the pivotal trial that established your recommended therapy. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, speaks with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, about one of oncology's most persistent challenges—the widening gap between carefully curated trial populations and the complex, real-world patients who enter clinics daily.

Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains uneven. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights a critical shift: moving AI from theoretical promise to practical application.

Think PFIC is only a pediatric disease? Think again. Progressive Familial Intrahepatic Cholestasis (PFIC) was long considered a condition exclusive to children. However, breakthroughs in genomic sequencing are revealing a hidden population: adults with "unexplained" cholestasis who are actually living with undiagnosed PFIC variants. Early identification is the difference between manageable care and irreversible liver damage. In this interview episode Dr. Aparna Goel, Stanford School of Medicine, and Dr. Laura Bull, UC San Francisco, break down the adult phenotype of PFIC and how clinicians can close the diagnostic gap. What You'll Hear In This Episode: The Adult Phenotype: Why adult cases often present as "indolent" or mild compared to the severe jaundice seen in infants. Diagnostic Red Flags: When to move beyond standard autoimmune panels and look for genetic markers. Genetic Testing 101: A comparison of targeted gene panels vs. whole exome sequencing for the most efficient diagnosis. The Power of a Name: How a specific PFIC diagnosis changes everything—from family counseling to starting life-altering IBAT inhibitors. 💡 Earn 1.5 Free CME/AAPA Credits 👉 Join the Escape Room: i3health.com/pfic

Read the full article at: https://oncdata.com/exploring-ai-helioliver Patients diagnosed with early-stage liver cancer have a significantly higher survival rate compared to those diagnosed in later stages, yet screening options and barriers persist. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Bharat Tewarie, MD, MBA, the CEO of Helio Genomics, about the company’s AI-powered blood test, HelioLiver, and its potential role in detecting hepatocellular carcinoma (HCC), the most common form of liver cancer. Dr. Tewarie shares why liver cancer is a strong use case for blood-based early detection, how HelioLiver may fit into existing workflows, and barriers to overcome for broader adoption.

The treatment of esophagogastric cancer is undergoing a profound transformation. In this episode, Yelena Janjigian, MD (MSKCC), discusses how perioperative chemoimmunotherapy and precision biomarkers are redefining the standard of care. Key highlights include: - The Perioperative Shift: Why starting immunotherapy before surgery is achieving unprecedented pathologic responses. - Precision Testing: The essential role of MSI, PD-L1, HER2, and CLDN18.2 testing for every patient. - Avoiding Understaging: Why clinical evaluation must go beyond imaging to prevent missed therapeutic opportunities. - Multidisciplinary Success: The critical need for surgeon-oncologist communication before the first incision. Tune in to learn why "cure" is the new benchmark in localized disease and how to integrate these advances into your clinical practice today. Interested in the complete CE activity? Complete Module 1: https://bit.ly/45u106o Complete Module 2: https://bit.ly/3HtOziO

Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.

Choosing Not to Treat: How Do You Know When the Best Treatment Is No Treatment? by i3 Health

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Don't forget to take the activity and claim your credit after the episode! Click here to take module 1 of the activity: bit.ly/3Y3ivHM

Hemophilia care is evolving faster than ever. Dr. Robert Sidonio, Jr., a leading expert from Children’s Healthcare of Atlanta, joins us to discuss the latest breakthroughs in research and clinical trials. From navigating new treatment options to the importance of personalized patient selection, Dr. Sidonio shares the "real-world" perspective clinicians need to stay ahead. Listen now to discover what the future holds for hemophilia management! Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj

Read the full article at: https://oncdata.com/inav-daniel-king Pancreatic cancer remains one of oncology’s most challenging diseases—fast-moving, hard to detect early, and often diagnosed after curative options have narrowed. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, speaks with Dr. Daniel King, Gastrointestinal Medical Oncologist at Northwell Health and co-inventor of iNav, an AI-enabled navigation platform designed to expedite diagnosis and treatment for patients with suspected pancreatic cancer.

Neuroendocrine tumor (NET) care is changing fast—and the pace of innovation is only accelerating. In this episode, Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), breaks down the latest advances that are reshaping how clinicians diagnose and treat NETs. Dr. Chauhan, who recently chaired i3 Health’s CME activity Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, returns to highlight what’s new and what matters most for practice. From evolving epidemiologic insights to emerging targeted therapies and next‑generation immunotherapies, he explains how these developments are expanding options for patients and refining real‑world decision making. Whether you’re a clinician treating NETs, a trainee looking to stay current, or a listener interested in where cancer care is headed next, this conversation offers a concise, high‑yield tour of the NET landscape—and where it’s going next. Click the link to view the full activity and claim your free CME credit: https://bit.ly/41Qo65Y Click here to download/view the infographic: https://bit.ly/4bbSUmL

Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-molecular-testing In the rapidly evolving landscape of modern oncology, molecular testing has emerged as one of the most powerful tools for personalizing patient care. However, this explosion of data has also created a "molecular testing chaos" that can overwhelm even the most seasoned clinicians. In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, sits down with Dr. Matthew Hadfield, Oncology Data Advisor Editor in Chief, to discuss whether we are over-testing, under-testing, or simply testing the wrong things at the wrong time. Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”

Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-financial-toxicity In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, explore how financial and geographic toxicities in oncology are, in reality, clinical toxicities. If a patient can’t afford to fill the prescription, is it really a treatment option? They discuss what financial toxicity truly means—far beyond drug prices—covering travel, parking, time off work, and the hidden costs of tests and therapies. Dr. Hadfield shares real-world examples of patients turning down innovative treatments and clinical trials because they can’t afford the logistical burden, and explains how geography and income create a two-tiered system of cancer care. The conversation examines how financial and geographic barriers distort shared decision making, limit participation in clinical trials, and skew our understanding of real-world efficacy. They also highlight the role of institutions, policymakers, and pharma in improving access, and why oncologists must reconsider ordering patterns, testing habits, and how they counsel patients about the full “cost” of care. Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month’s topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”

Psoriatic arthritis management is evolving fast, but bridging the gap between clinical evidence and patient experience remains the ultimate challenge. When multidisciplinary teams and patients truly sync, care transforms. i3 Health recently convened a Multidisciplinary Task Force to discuss early screening, comorbidities, and therapeutic optimization. In this exclusive follow-up interview, we sit down with Archie Franklin, MBA—a veteran PsA patient and Task Force moderator—to go beyond the data. Listen now to hear a unique, dual-perspective look at the changing treatment landscape, sharing candid reflections on how clinicians can bridge communication gaps and practically elevate outcomes for every patient. Click the link to view the Task Force and claim your free CME/NCPD/CPE credit: https://bit.ly/4h5NSKb

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health’s CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 1 of the full podcast activity. Click the link to complete module 1 and claim your free credit: bit.ly/4iYmYD2

Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available. You can catch the live session on either of these dates: Wednesday, January 8 at 5:00 pm ET: https://bit.ly/4iZxnA0 Monday, January 26 at 5:00 pm ET: https://bit.ly/4qALw9J

Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies. The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best! Tuesday, January 13 at 5:00 pm ET - bit.ly/4p7HRil Monday, February 2 at 7:00 pm ET - bit.ly/495gnEd

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 2 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies" Don't forget to claim your credit after the episode! Click on the link to claim your credit for module 2: bit.ly/43VoFNP

Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 1 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies" Don't forget to claim your credit after the episode! Click on the link to claim your credit for module 1: bit.ly/3Y3ivHM Click here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP

Read the full article at: https://oncdata.com/travis-osterman-ai-informatics In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Dr. Travis Osterman, Director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center, about the evolving role of health informatics in oncology. Their conversation spans training pathways, precision oncology, data standards, AI integrations, and the strategies to promote adoption in both academic and community practices.

Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies. 🎧 Listen now and click the link to claim your CE credit! Claim your credit here: bit.ly/4pGrLO5 🔗 Learn more and access continuing education activities: i3health.com 📲 Stay connected with i3 Health: Twitter/X: https://bit.ly/3ITDaJV Facebook: https://bit.ly/46wmwJo YouTube: https://bit.ly/46PXLXx 🎧 Subscribe to the Oncology Data Advisor Podcast on your favorite streaming platform so you never miss the latest expert discussions!

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets. Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs! Click the link to claim your CE credit:

Click here to view the full article on Oncology Data Advisor: https://oncdata.com-ai-ascomind ASCOmind is a novel artificial intelligence (AI) framework designed to help clinicians, researchers, and industry teams synthesize the vast amount of data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Xiaoyan Wang, PhD, Research Professor at Tulane University, and William Oh, MD, Professor of Internal Medicine at Yale School of Medicine, about the development, integration, and benefits of this valuable tool.

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now! Click here to claim credit for this activity: https://bit.ly/3HtOziO Click here to listen to Module 1 of this series: https://bit.ly/45u106o

Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD. In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now! Click here to claim you CE credit for this activity: https://bit.ly/45u106o Click here to continue listening to Module 2 of this series: https://bit.ly/3HtOziO

Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians. Click here to complete the free CME/NCPD/CE activity: bit.ly/3HqXjpX

i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity! Click below to complete the claim your CE credit: Module 2: https://bit.ly/405xEJO Click below to complete the Module 1 from this series, HER2 in NSCLC: Actionable Insights and Testing Recommendations Module 1: https://bit.ly/49NCaQu

i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC). In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity! Click below to complete the claim your CE credit: Module 1: https://bit.ly/49NCaQu Click below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLC Module 2: https://bit.ly/405xEJO

oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM. In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration. Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you! Register Here: bit.ly/3UgV7nF

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education. Click the links below for the full CME activity! Module 1: https://bit.ly/3X8apxa Module 2 : https://bit.ly/41rS14I Module 3: https://bit.ly/4b9JU00 And view the slide decks here: Module 1: https://bit.ly/4l0NTzc Module 2: https://bit.ly/4fdXwti Module 3: https://bit.ly/40AkmoP

As research in dedifferentiated liposarcoma (DDLPS) continues to advance, the importance of multidisciplinary collaboration and access to innovative therapies remains at the forefront of patient care. Recently, Dr. Richard Riedel of Duke Cancer Institute and Dr. Candace Haddox of Dana-Farber Cancer Institute co-chaired i3 Health’s DDLPS Task Force activity, which brought together a panel of experts to address the complexities of this rare and challenging sarcoma subtype. With new clinical trials underway and a growing understanding of the disease’s molecular landscape, Dr. Riedel and Dr. Haddox sat down to highlight promising research directions and insights in honor of Sarcoma Awareness Month in July. After listening to the interview, stay tuned to hear the full accredited podcast with Dr. Riedel and Dr. Haddox, and click the link below to claim free CME/AAPA credit. Click the links below for the Task Force activity! - Accredited CME/AAPA Podcast: i3health.com/course-information/podcast-ddlps - Position Statement Published in Cancer Treatment Reviews: www.cancertreatmentreviews.com/article/S…/fulltext - Live Task Force Recording: youtu.be/Otr5_tiFQ68

Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs. In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration. Don’t miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you! Register Here! July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registration August 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration

A Return on Humanity: How the American Cancer Society Uses AI to Improve Patient Care by i3 Health

Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape. Click here to claim your credit for this podcast:

Read the full article for this interview here: https://oncdata.com/standard-model-biomedicine Artificial intelligence (AI) is rapidly transforming the landscape of oncology, offering new tools to improve patient care and accelerate research. In this episode of Exploring AI in Oncology, Dr. Waqas Haque sat down with Kevin Brown, Founder and CEO of Standard Model Biomedicine, to discuss the challenges and opportunities of implementing AI in cancer care.

Read the full article here: https://oncdata.com/reimagining-oncology-nursing-through-ai In this episode of the Exploring AI in Oncology series, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Kathleen McGrow, Sangeeta Agarawal, and Marc Perkins-Carrillo about their presentation at the Oncology Nursing Society (ONS) Congress about the intersection of artificial intelligence (AI) and oncology nursing. Their conversation highlights the transformative potential of AI in nursing, the skills needed to navigate this evolving landscape, and the ethical considerations that must guide its implementation.

In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments. Click here to go back and listen to module 1 of this podcast series: https://bit.ly/4iYmYD2 Click here to claim your CME/NCPD credit: https://bit.ly/44yO9RB

Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually. Click here to listen to module 2 of this podcast series: bit.ly/44yO9RB Click here to claim your CME/NCPD credit: bit.ly/4iYmYD2

In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai’s innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.

The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical. In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease. Don’t miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice. Click below to access these valuable resources: Accredited CME/NCPD Podcast: bit.ly/3B4gSB1 Position Statement in Blood Cancer Journal: www.nature.com/articles/s41408-024-01129-0 Live Task Force Recording: www.youtube.com/live/TILCPB6w3Ig?…=1Z8m4dA2qwLJd6rN

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month. Click the link for the full activity! https://bit.ly/4hyVwLn

As we recognize Kidney Cancer Awareness Month this March, advancements in renal cell carcinoma (RCC) treatment continue to evolve. Recently, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, a Nurse Practitioner and expert in genitourinary oncology, chaired the i3 Health’s NCPD activity titled Toxicity Management and Symptom Control in Advanced RCC: Playbook Update. In this interview, she shares updates in RCC treatment, strategies for toxicity management, and the importance of patient education. Click here for the full NCPD activity! https://i3health.com/course-information/toxicity-management-and-symptom-control-in-advanced-rcc-playbook-update

In this episode of the Exploring Artificial Intelligence (AI) in Oncology series, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Osama Khan, MD, Staff Pathologist at Natera, a cell-free DNA (cfDNA) technology company that aims to make personalized genetic testing and diagnostics part of the standard of care. Dr. Khan shares insights into how digital pathology and emerging technologies like AI and measurable residual disease (MRD) testing are revolutionizing oncology, driving precision medicine, and enhancing patient care. Learn more at: https://oncdata.com/digital-pathology-osama-khan

The role of artificial intelligence (AI) and machine learning (ML) in precision oncology has expanded rapidly, offering promising tools for clinicians and researchers to deliver more targeted and efficient care. During the 2024 San Antonio Breast Cancer Symposium (SABCS), Fellows Forum member Dr. Jasmin Hundal conducted an interview with Ian Maurer, Chief Technology Officer at GenomOncology, to explore the applications, challenges, and future directions of AI in oncology. Learn more at: https://oncfellows.com/how-ai-is-revolutionizing-precision-oncology

Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel’s innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney